Radiation oncology journal最新文献

{"title":"Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer.","authors":"Byoung Hyuck Kim,&nbsp;Jae Sik Kim,&nbsp;Hak Jae Kim","doi":"10.3857/roj.2023.00430","DOIUrl":"10.3857/roj.2023.00430","url":null,"abstract":"<p><p>Despite conventionally applied postoperative radiotherapy (PORT) in pathological N2 (pN2) stage non-small cell lung cancer (NSCLC) considering high locoregional recurrence, its survival benefit has been a continuous topic of debate. Although several randomized clinical trials have been conducted, many of them have been withdrawn or analyzed without statistical significance due to slow accrual, making it difficult to determine the efficacy of PORT. Recently, the results of large-scale randomized clinical trials have been published, which showed some improvement in disease-free survival with PORT, but finally had no impact on overall survival. Based on these results, it was expected that the debate over PORT in pN2 patients with NSCLC would come to an end. However, since pN2 patients have different clinicopathologic features, it has become more important to carefully select the patient population who will benefit from PORT. In addition, given the development of systemic treatments such as molecular-targeted therapy and immunotherapy, it is crucial to evaluate whether there is any benefit to PORT in the midst of these recent changes. Therefore, determining the optimal treatment approach for NSCLC pN2 patients remains a complex issue that requires further research and evaluation.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"144-153"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/01/roj-2023-00430.PMC10556840.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of surface-guided radiation therapy in prostate cancer: comparative analysis of differences with skin marking-guided patient setup.","authors":"Jaeha Lee,&nbsp;Yeon Joo Kim,&nbsp;Youngmoon Goh,&nbsp;Eunyeong Yang,&nbsp;Ha Un Kim,&nbsp;Si Yeol Song,&nbsp;Young Seok Kim","doi":"10.3857/roj.2023.00521","DOIUrl":"10.3857/roj.2023.00521","url":null,"abstract":"<p><strong>Purpose: </strong>Surface-guided radiation therapy is an image-guided method using optical surface imaging that has recently been adopted for patient setup and motion monitoring during treatment. We aimed to determine whether the surface guide setup is accurate and efficient compared to the skin-marking guide in prostate cancer treatment.</p><p><strong>Materials and methods: </strong>The skin-marking setup was performed, and vertical, longitudinal, and lateral couch values (labeled as \"M\") were recorded. Subsequently, the surface-guided setup was conducted, and couch values (labeled as \"S\") were recorded. After performing cone-beam computed tomography (CBCT), the final couch values was recorded (labeled as \"C\"), and the shift value was calculated (labeled as \"Gap (M-S),\" \"Gap (M-C),\" \"Gap (S-C)\") and then compared. Additionally, the setup times for the skin marking and surface guides were also compared.</p><p><strong>Results: </strong>One hundred and twenty-five patients were analyzed, totaling 2,735 treatment fractions. Gap (M-S) showed minimal differences in the vertical, longitudinal, and lateral averages (-0.03 cm, 0.07 cm, and 0.06 cm, respectively). Gap (M-C) and Gap (S-C) exhibited a mean difference of 0.04 cm (p = 0.03) in the vertical direction, a mean difference of 0.35 cm (p = 0.52) in the longitudinal direction, and a mean difference of 0.11 cm (p = 0.91) in the lateral direction. There was no correlation between shift values and patient characteristics. The average setup time of the skin-marking guide was 6.72 minutes, and 7.53 minutes for the surface guide.</p><p><strong>Conclusion: </strong>There was no statistically significant difference between the surface and skin-marking guides regarding final CBCT shift values and no correlation between translational shift values and patient characteristics. We also observed minimal difference in setup time between the two methods. Therefore, the surface guide can be considered an accurate and time-efficient alternative to skin-marking guides.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"172-177"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/71/roj-2023-00521.PMC10556842.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of dose-escalated intensity-modulated radiotherapy for limited disease small cell lung cancer.","authors":"Eunyeong Yang,&nbsp;Young Seob Shin,&nbsp;Ji Hyeon Joo,&nbsp;Wonsik Choi,&nbsp;Su Ssan Kim,&nbsp;Eun Kyung Choi,&nbsp;Jaeha Lee,&nbsp;Si Yeol Song","doi":"10.3857/roj.2023.00591","DOIUrl":"10.3857/roj.2023.00591","url":null,"abstract":"<p><strong>Purpose: </strong>An optimal once-daily radiotherapy (RT) regimen is under investigation for definitive concurrent chemoradiotherapy (CCRT) in limited disease small cell lung cancer (LD-SCLC). We compared the efficacy and safety of dose escalation with intensity-modulated radiotherapy (IMRT).</p><p><strong>Materials and methods: </strong>Between January 2016 and March 2021, patients treated with definitive CCRT for LD-SCLC with IMRT were retrospectively reviewed. Patients who received a total dose <50 Gy or those with a history of thoracic RT or surgery were excluded. The patients were divided into two groups (standard and dose-escalated) based on the total biologically effective dose (BED, α/β = 10) of 70 Gy. The chemotherapeutic regimen comprised four cycles of etoposide and cisplatin.</p><p><strong>Results: </strong>One hundred and twenty-two patients were analyzed and the median follow-up was 27.8 months (range, 4.4 to 76.9 months). The median age of the patients was 63 years (range, 35 to 78 years) and the majority had a history of smoking (86.0%). The 1- and 3-year overall survival rates of the escalated dose group were significantly higher than those of the standard group (93.5% and 50.5% vs. 76.7% and 33.3%, respectively; p = 0.008), as were the 1- and 3-year freedom from in-field failure rates (91.4% and 66.5% vs. 73.8% and 46.9%, respectively; p = 0.018). The incidence of grade 2 or higher acute and late pneumonitis was not significantly different between the two groups (p = 0.062, 0.185).</p><p><strong>Conclusion: </strong>Dose-escalated once-daily CCRT with IMRT led to improved locoregional control and survival, with no increase in toxicity.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"199-208"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/8e/roj-2023-00591.PMC10556837.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}